Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $91.9M | $158M | $60.1M | $64.2M | $105M | $77.4M | $152M | $58.7M | $150M | $150M |
| Revenue growth | — | 71.7% | -61.9% | 6.8% | 63.4% | -26.2% | 96.2% | -61.3% | 155.3% | -0.3% |
| Operating income | -$60.0M | -$22.1M | -$171M | -$177M | -$131M | -$203M | -$121M | -$168M | -$111M | -$72.8M |
| Operating margin | -65.3% | -14.0% | -284.8% | -276.0% | -125.0% | -261.9% | -79.9% | -286.4% | -73.7% | -48.7% |
| Net income | -$58.5M | -$19.6M | -$171M | -$152M | -$130M | -$202M | -$120M | -$9.06M | -$67.0M | -$74.6M |
| Net margin | -63.7% | -12.4% | -285.2% | -236.5% | -123.7% | -261.0% | -78.8% | -15.4% | -44.7% | -49.9% |
| EPS (diluted) | -$1.69 | -$0.54 | — | — | -$2.47 | -$3.37 | -$1.95 | -$0.15 | -$1.07 | -$1.18 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.7M | $14.4M | -$153M | -$134M | -$112M | -$144M | -$87.0M | -$78.2M | -$68.4M | -$81.0M |
| Capital expenditures | $11.4M | $29.4M | $25.0M | $4.29M | $5.91M | $6.20M | $3.62M | $1.76M | $3.71M | $1.91M |
| Free cash flow | -$55.1M | -$15.0M | -$178M | -$139M | -$118M | -$150M | -$90.6M | -$80.0M | -$72.1M | -$83.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $84.1M | $212M | $220M | $126M | $181M | $123M | $109M | $101M | $183M | $57.2M |
| Total assets | $311M | $374M | $332M | $313M | $379M | $335M | $280M | $298M | $262M | $257M |
| Total liabilities | $42.5M | $74.6M | $89.3M | $81.9M | $82.9M | $95.6M | $138M | $146M | $146M | $201M |
| Shareholders' equity | $269M | $299M | $243M | $231M | $296M | $240M | $142M | $153M | $116M | $55.6M |
| Retained earnings | -$293M | -$312M | -$490M | -$642M | -$772M | -$974M | -$1.09B | -$1.10B | -$1.17B | -$1.24B |
| Shares (wtd avg diluted) | 34.7M | 36.1M | 42.4M | 48.1M | 52.4M | 59.9M | 61.4M | 61.9M | 62.6M | 63.2M |
Every figure is extracted from MACROGENICS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.